We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Sandoz Says Two Indian Sites Hit With a Warning Letter for CGMP Issues
Sandoz Says Two Indian Sites Hit With a Warning Letter for CGMP Issues
Novartis’ generics unit Sandoz received a warning letter from the FDA citing cGMP deficiencies for finished drugs at the company’s plants in Kalwe and Turbhe, India.